The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab
Abstract
Objective: The impact of present disease‐modifying treatments (DMTs) in multiple sclerosis (MS) on nerve injury and reactive astrogliosis is still unclear. Therefore, we studied the effect of natalizumab treatment on the release of 2 brain‐specific tissue damage markers into cerebrospinal fluid (CSF) in MS patients. Methods: CSF samples from 92 patients with relapsing forms of MS were collected in a prospective manner prior to natalizumab treatment and after 6 or 12 months. In 86 cases, natalizumab was used as second‐line DMT due to breakthrough of disease activity. The levels of neurofilament light (NFL) and glial fibrillary acidic protein (GFAP) were determined using highly sensitive in‐house developed enzyme‐linked immunosorbent assays. Results: Natalizumab treatment led to a 3‐fold reduction of NFL levels, from a mean value of 1,300 (standard deviation [SD], 2,200) to 400 (SD, 270) ng/l (p < 0.001). The later value was not significantly different from that found in healthy control subjects (350ng/l; SD, 170; n = 28). Subgroup analysis revealed a consistent effect on NFL release, regardless of previous DMT or whether patients had relapses or were in remission within 3 months prior to natalizumab treatment. No differences between pre‐ and post‐treatment levels of GFAP were detected. Interpretation: Our data demonstrate that natalizumab treatment reduces the accumulation of nerve injury in relapsing forms of MS. It is anticipated that highly effective anti‐inflammatory treatment can reduce axonal loss, thereby preventing development of permanent neurological disability. Ann Neurol 2010
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
Kurtzke, J. F. (1983) · Neurology · doi:10.1212/wnl.33.11.1444 · Cited by 15,011
Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”
Polman, C. H., Reingold, S. C., Edan, G., Filippi, M., Hartung, H., Kappos, L., Lublin, F. D., Metz, L. M., McFarland, H. F., O'Connor, P. W., et al. (2005) · Annals of Neurology · doi:10.1002/ana.20703 · Cited by 5,017
Axonal transection in the lesions of multiple sclerosis
Trapp, B. D., Peterson, J., Ransohoff, R. M., Rudick, R., Mörk, S., & Bö, L. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801293380502 · Cited by 4,029
A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
Polman, C. H., O'Connor, P. W., Havrdova, E., Hutchinson, M., Kappos, L., Miller, D. H., Phillips, J. T., Lublin, F. D., Giovannoni, G., Wajgt, A., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa044397 · Cited by 3,386
Diagnostic criteria for multiple sclerosis
Poser, C. M., & Brinar, V. V. (2001) · Clinical Neurology and Neurosurgery · doi:10.1016/s0303-8467(00)00125-6 · Cited by 1,283
Evidence of Axonal Damage in the Early Stages of Multiple Sclerosis and Its Relevance to Disability
De Stefano, N., Narayanan, S., Francis, G. S., Arnaoutelis, R., Tartaglia, M. C., Antel, J. P., Matthews, P. M., & Arnold, D. L. (2001) · Archives of Neurology · doi:10.1001/archneur.58.1.65 · Cited by 505
Havrdova, E., Galetta, S., Hutchinson, M., Stefoski, D., Bates, D., Polman, C. H., O'Connor, P. W., Giovannoni, G., Phillips, J. T., Lublin, F. D., et al. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70021-3 · Cited by 471
Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis
Filippi, M. (2003) · Brain · doi:10.1093/brain/awg038 · Cited by 371
MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS
Miller, D. H., Soon, D., Fernando, K. T., MacManus, D. G., Barker, G. J., Yousry, T. A., Fisher, E., O'Connor, P. W., Phillips, J. T., Polman, C. H., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000260064.77700.fd · Cited by 332
Cited by
Neurofilaments as biomarkers in neurological disorders
Khalil, M., Teunissen, C. E., Otto, M., Piehl, F., Sormani, M. P., Gattringer, T., Barro, C., Kappos, L., Comabella, M., Fazekas, F., et al. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0058-z · Cited by 1,988
Self-citationFilippi, M., Bar-Or, A., Piehl, F., Preziosa, P., Solari, A., Vukusic, S., & Rocca, M. A. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0041-4 · Cited by 1,562
Self-citationNeurofilament light chain as a biomarker in neurological disorders
Gaetani, L., Blennow, K., Calabresi, P., Di Filippo, M., Parnetti, L., & Zetterberg, H. (2019) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2018-320106 · Cited by 1,334
Serum neurofilament light: a biomarker of neuronal damage in multiple sclerosis
Disanto, G., Barro, C., Benkert, P., Naegelin, Y., Schädelin, S., Giardiello, A., Zecca, C., Blennow, K., Zetterberg, H., Leppert, D., et al. (2017) · Annals of Neurology · doi:10.1002/ana.24954 · Cited by 1,164
Bridel, C., van Wieringen, W. N., Zetterberg, H., Tijms, B. M., Teunissen, C. E., and the NFL Group, Alvarez-Cermeño, J. C., Andreasson, U., Axelsson, M., Bäckström, D. C., et al. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.1534 · Cited by 764
Self-citationMechanisms of neurodegeneration and axonal dysfunction in multiple sclerosis
Friese, M. A., Schattling, B., & Fugger, L. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.37 · Cited by 628
Blood neurofilament light chain as a biomarker of MS disease activity and treatment response
Kuhle, J., Kropshofer, H., Haering, D. A., Kundu, U., Meinert, R., Barro, C., Dahlke, F., Tomic, D., Leppert, D., & Kappos, L. (2019) · Neurology · doi:10.1212/wnl.0000000000007032 · Cited by 568
Barro, C., Benkert, P., Disanto, G., Tsagkas, C., Amann, M., Naegelin, Y., Leppert, D., Gobbi, C., Granziera, C., Yaldizli, Ö., et al. (2018) · Brain · doi:10.1093/brain/awy154 · Cited by 517
Nylander, A., & Hafler, D. A. (2012) · Journal of Clinical Investigation · doi:10.1172/jci58649 · Cited by 495
Increased Neurofilament Light Chain Blood Levels in Neurodegenerative Neurological Diseases
Gaiottino, J., Norgren, N., Dobson, R., Topping, J., Nissim, A., Malaspina, A., Bestwick, J. P., Monsch, A. U., Regeniter, A., Lindberg, R. L., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0075091 · Cited by 486
Self-citationGisslén, M., Price, R. W., Andreasson, U., Norgren, N., Nilsson, S., Hagberg, L., Fuchs, D., Spudich, S., Blennow, K., & Zetterberg, H. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2015.11.036 · Cited by 481
Self-citationMonitoring disease activity in multiple sclerosis using serum neurofilament light protein
Novakova, L., Zetterberg, H., Sundström, P., Axelsson, M., Khademi, M., Gunnarsson, M., Malmeström, C., Svenningsson, A., Olsson, T., Piehl, F., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000004683 · Cited by 426
Self-citationNeurofilaments: neurobiological foundations for biomarker applications
Gafson, A. R., Barthélemy, N. R., Bomont, P., Carare, R. O., Durham, H. D., Julien, J.-P., Kuhle, J., Leppert, D., Nixon, R. A., Weller, R. O., et al. (2020) · Brain · doi:10.1093/brain/awaa098 · Cited by 325
Thelin, E. P., Nelson, D. W., & Bellander, B.-M. (2017) · Acta Neurochirurgica · doi:10.1007/s00701-016-3046-3 · Cited by 317
Lewczuk, P., Riederer, P., O’Bryant, S. E., Verbeek, M. M., Dubois, B., Visser, P. J., Jellinger, K. A., Engelborghs, S., Ramirez, A., Parnetti, L., et al. (2018) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2017.1375556 · Cited by 307
Boxer, A. L., Lang, A. E., Grossman, M., Knopman, D. S., Miller, B. L., Schneider, L. S., Doody, R. S., Lees, A., Golbe, L. I., Williams, D. R., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70088-2 · Cited by 294
Ganglion Cell Loss in Relation to Visual Disability in Multiple Sclerosis
Walter, S. D., Ishikawa, H., Galetta, K. M., Sakai, R. E., Feller, D. J., Henderson, S. B., Wilson, J. A., Maguire, M. G., Galetta, S. L., Frohman, E., et al. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2011.11.032 · Cited by 294
Reaching an evidence-based prognosis for personalized treatment of multiple sclerosis
Rotstein, D., & Montalban, X. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0170-8 · Cited by 289
Serum Neurofilament Light Chain Levels in Patients With Presymptomatic Multiple Sclerosis
Bjornevik, K., Munger, K. L., Cortese, M., Barro, C., Healy, B. C., Niebuhr, D. W., Scher, A. I., Kuhle, J., & Ascherio, A. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2019.3238 · Cited by 269
Kuhle, J., Barro, C., Disanto, G., Mathias, A., Soneson, C., Bonnier, G., Yaldizli, Ö., Regeniter, A., Derfuss, T., Canales, M., et al. (2016) · Multiple Sclerosis Journal · doi:10.1177/1352458515623365 · Cited by 257
Body fluid biomarkers in multiple sclerosis
Comabella, M., & Montalban, X. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70233-3 · Cited by 258
The utility of cerebrospinal fluid analysis in patients with multiple sclerosis
Stangel, M., Fredrikson, S., Meinl, E., Petzold, A., Stüve, O., & Tumani, H. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2013.41 · Cited by 229
Cantó, E., Barro, C., Zhao, C., Caillier, S. J., Michalak, Z., Bove, R., Tomic, D., Santaniello, A., Häring, D. A., Hollenbach, J., et al. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.2137 · Cited by 199
Neurofilament Light: A Dynamic Cross-Disease Fluid Biomarker for Neurodegeneration
Zetterberg, H. (2016) · Neuron · doi:10.1016/j.neuron.2016.06.030 · Cited by 197
Picca, A., Guerra, F., Calvani, R., Romano, R., Coelho-Júnior, H. J., Bucci, C., & Marzetti, E. (2021) · Biomolecules · doi:10.3390/biom11101508 · Cited by 189
Mechanisms of Neurodegeneration and Axonal Dysfunction in Progressive Multiple Sclerosis
Correale, J., Marrodan, M., & Ysrraelit, M. C. (2019) · Biomedicines · doi:10.3390/biomedicines7010014 · Cited by 167
Alirezaei, Z., Pourhanifeh, M. H., Borran, S., Nejati, M., Mirzaei, H., & Hamblin, M. R. (2020) · Molecular Neurobiology · doi:10.1007/s12035-019-01698-3 · Cited by 142
Sejbaek, T., Nielsen, H. H., Penner, N., Plavina, T., Mendoza, J. P., Martin, N. A., Elkjaer, M. L., Ravnborg, M. H., & Illes, Z. (2019) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2019-321321 · Cited by 108
Rojas, J. C., Wang, P., Staffaroni, A. M., Heller, C., Cobigo, Y., Wolf, A., Goh, S.-Y. M., Ljubenkov, P. A., Heuer, H. W., Fong, J. C., et al. (2021) · Neurology · doi:10.1212/wnl.0000000000011848 · Cited by 106
Blood Neurofilament Light Chain: The Neurologist’s Troponin?
Thebault, S., Booth, R. A., & Freedman, M. S. (2020) · Biomedicines · doi:10.3390/biomedicines8110523 · Cited by 101
Cerebrospinal fluid lactate is associated with multiple sclerosis disease progression
Albanese, M., Zagaglia, S., Landi, D., Boffa, L., Nicoletti, C. G., Marciani, M. G., Mandolesi, G., Marfia, G. A., Buttari, F., Mori, F., et al. (2016) · Journal of Neuroinflammation · doi:10.1186/s12974-016-0502-1 · Cited by 88
Brureau, A., Blanchard-Bregeon, V., Pech, C., Hamon, S., Chaillou, P., Guillemot, J.-C., Barneoud, P., Bertrand, P., Pradier, L., Rooney, T., et al. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2017.04.007 · Cited by 62
Cerebrospinal fluid biomarkers of β-amyloid metabolism in multiple sclerosis
Augutis, K., Axelsson, M., Portelius, E., Brinkmalm, G., Andreasson, U., Gustavsson, M. K., Malmeström, C., Lycke, J., Blennow, K., Zetterberg, H., et al. (2013) · Multiple Sclerosis Journal · doi:10.1177/1352458512460603 · Cited by 47
Self-citationSerum GFAP and NfL levels in benign relapsing-remitting multiple sclerosis
Niiranen, M., Kontkanen, A., Jääskeläinen, O., Tertsunen, H.-M., Selander, T., Hartikainen, P., Huber, N., Solje, E., Haapasalo, A., Kokkola, T., et al. (2021) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2021.103280 · Cited by 25
Autoimmune encephalomyelitis in NOD mice is not initially a progressive multiple sclerosis model
Baker, D., Nutma, E., O'Shea, H., Cooke, A., Orian, J. M., & Amor, S. (2019) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.792 · Cited by 21
“22,36 Glial cell inflammation is thought to be part of the substrate for slow progressive nerve loss in MS. 11 However, the loss of axons and myelin, accumulation of microglial activation and gliosis reported in progressive EAE models, 24–31 is not qualitatively different from that found following the accumulation of d…”
Metadata
- Authors
- Gunnarsson, M., Malmeström, C., Axelsson, M., Sundström, P., Dahle, C., Vrethem, M., Olsson, T., Piehl, F., Norgren, N., Rosengren, L., Svenningsson, A., & Lycke, J.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2010-12-08
- Volume
- 69
- Issue
- 1
- Pages
- 83-89
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W2150429740
- Cited by
- 345
- References
- 28
- FWCI
- 10.77
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.